Gujarat-based SAVA Healthcare conducted the groundbreaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March, 2024. 

This greenfield project will expand the manufacturing capabilities of SAVA Healthcare as well as create 1,000-plus employment opportunities, offering advanced skill development for the local talent pool.

The proposed second plant at Indore will have a projected annual production capacity of 2,351.3 million SKUs which will include tablets, capsules, dry powder for oral suspension, ointments, nasal sprays and dry powders for inhalation. By expanding manufacturing capabilities, it will also elevate Indore’s position in the pharmaceutical landscape.

Situated on 13.8 acres of prime land, the forthcoming facility will meet stringent regulatory standards such as EUGMP/USFDA of global pharma markets. The construction of the facility is slated to be executed in two planned phases. The first phase with a built-up area of 29,000 sq. mtrs. is targeted for completion within a year, while the second phase will be completed by 2026. SAVA Healthcare currently operates a Health Canada, PIC/s approved facility in Surendranagar, Gujarat and has an R&D centre in Pune. 

The new manufacturing facility will cater to the growing demand for quality pharmaceuticals in India and globally. Through this expansion, it will additionally create employment opportunities for the people in the region. SAVA Healthcare exports pharma products to more than 35 countries including Canada, Ukraine, the CIS, Asia and Africa. Known for its expertise in Nasal Drug Delivery Platforms, SAVA’s CRAMS division caters to Indian and international companies.